SCHEMBL308570

SCHEMBL308570

COC(=O)c1cccc(NC(N)=O)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.77
RAB9A P51151 7/20 0.69
NPC1 O15118 5/20 0.65
MAPT P10636 4/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
TP53 P04637 1/20 0.61
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
POLB P06746 1/20 0.59
HTT P42858 1/20 0.58
HPGD P15428 1/20 0.57
GPR17 Q13304 1/20 0.57
NPSR1 Q6W5P4 1/20 0.56
ABL1 P00519 1/20 0.56
RIN1 Q13671 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL983433 0.87 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL7975430 0.87 ALDH1A1 (0.72) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL307662 0.85 ALDH1A1 (0.56) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL863169 0.84 RAB9A (0.71) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL11654124 0.84 RAB9A (0.71) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL8123409 0.84 KMT2A (0.68) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL27453091 0.84 ALDH1A1 (0.56) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL4795890 0.84 KMT2A (0.66) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL6242208 0.83 RAB9A (0.84) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2138281 0.82 ALDH1A1 (0.66) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382303-A1 NOVEL COMPOUND AS NADPH OXIDASE 2 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2025-12-18 US disclosed
EP-4549441-A1 NOVEL COMPOUND AS NADPH OXIDASE 2 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Dongguk University Industry-Academic Cooperation Foundation (KR) 2025-05-07 EP disclosed
US-12060362-B2 Inhibitors of glucose transporters (GLUTs) LEAD DISCOVERY CENTER GMBH (DE) 2024-08-13 US disclosed
WO-2024005526-A1 NOVEL COMPOUND AS NADPH OXIDASE 2 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 동국대학교 산학협력단 2024-01-04 WO disclosed
WO-2024005506-A1 NOVEL COMPOUND WITH INHIBITORY ACTIVITY AGAINST NADPH OXIDASE 2 (NOX2) AND USE THEREOF 동국대학교 산학협력단 2024-01-04 WO disclosed
EP-3814359-B1 INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTS) LEAD DISCOVERY CENTER GMBH (DE) 2022-08-17 EP disclosed
US-20210198269-A1 INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-07-01 US disclosed
US-20210198269-A1 INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-07-01 US disclosed
EP-3814359-A1 INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTS) Lead Discovery Center GmbH (DE) 2021-05-05 EP disclosed
WO-2018045969-A1 COMPOUND FOR ACTIVATING ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE 法玛科技顾问股份有限公司 2018-03-15 WO disclosed
US-20100041645-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 US disclosed
US-20100041645-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 US disclosed
EP-2114869-A1 RHO KINASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2009-11-11 EP disclosed
WO-2008086047-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-17 WO disclosed
WO-2008086047-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-17 WO disclosed
CN-1130351-C 1,5-benzodiazepine derivatives ZERIA PHARM CO LTD (JP) 2003-12-10 CN disclosed
EP-0628033-B1 BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS YAMANOUCHI PHARMA CO LTD (JP) 2003-07-23 EP disclosed
CN-1246850-A 1,5-benzodiazepine derivatives ZERIA PHARM CO LTD (JP) 2000-03-08 CN disclosed
EP-0628033-A1 BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1994-12-14 EP disclosed
CN-1075717-A Benzodiazepine * derivatives YAMANOUCHI PHARMA CO LTD (JP) 1993-09-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060362-B2 Inhibitors of glucose transporters (GLUTs) SLC2A1, SLC2A3, SLC2A4 ALDH1A1 364/4885RAB9A 3217/4885NPC1 549/4885
US-20100041645-A1 RHO KINASE INHIBITORS CIT, ROCK1, RHOT2 ALDH1A1 3661/4885RAB9A 214/4885NPC1 3330/4885
US-20210198269-A1 INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) SLC2A1, SLC2A3, SLC2A4 ALDH1A1 515/4885RAB9A 3223/4885NPC1 555/4885
US-20250382303-A1 NOVEL COMPOUND AS NADPH OXIDASE 2 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CYBB, NOX4, NOX1 ALDH1A1 565/4885RAB9A 2808/4885NPC1 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.